A study to investigate NPS and symptoms in Chinese adult participants with CRSwNP initiating treatment with tezepelumab

Trial Identifier: D5242L00001
Sponsor: AstraZeneca
Start Date: April 2026
Primary Completion Date: March 2028
Study Completion Date: March 2028
Condition: Nose and Sinus Disorder

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China, 100730
China Beijing, China, 100034
China Beijing, China, 100191
China Cangzhou, China, 061000
China Changchun, China
China Changsha, China
China Chengdu, China, 610041
China Chengdu, China, 610021
China Chongqing, China
China Foshan, China, 528000
China Fuzhou, China, 350005
China Guiyang, China, 550044
China Hefei, China, 230601
China Hefei, China
China Huaian, China, 223300
China Kunming, China
China Lanzhou, China, 730030
China Nanchang, China
China Nanning, China
China Ningbo, China
China Qingdao, China
China Shanghai, China
China Shenzhen, China, 518039
China Shijiazhuang, China, 50051
China Taiyuan, China, 030001
China Taizhou, China, 225300
China Tianjin, China
China Wuhan, China, 430022
China Wuhu, China, 241004
China Xian, China, 710004
China Yangzhou, China, 225000
China Zibo, China, 255036